Investors who lost money on fulcrum therapeutics, inc. should contact levi & korsinsky about an ongoing investigation - fulc

New york, ny / accesswire / october 10, 2024 / levi & korsinsky notifies investors that it has commenced an investigation of fulcrum therapeutics, inc. ("fulcrum therapeutics, inc.") (nasdaq:fulc) concerning possible violations of federal securities laws. fulcrum announced on september 12, 2024, that "its phase 3 reach trial evaluating losmapimod in patients with fshd, did not achieve its primary endpoint of change from baseline in rsa with losmapimod compared to placebo.
FULC Ratings Summary
FULC Quant Ranking